TrialEmerging microbes & infections2024

Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China.

Ying Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.